Achievement of Remission Defined by Absence of Objective Signs of Inflammation versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies
Gensler LS, Marzo-Ortega H, Taieb V, Voiniciuc D, Marten A, Stojan G, Kim M, Rudwaleit M (2024)
In: 2024 Abstract Supplement ACR Convergence 2024 November 15–19, 2024 Washington, DC. Arthritis & Rheumatology , 76(Suppl. 9). Hoboken: Wiley: 4772-4775.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Gensler, Lianne S.;
Marzo-Ortega, Helena;
Taieb, Vanessa;
Voiniciuc, Diana;
Marten, Alexander;
Stojan, George;
Kim, Mindy;
Rudwaleit, MartinUniBi
Einrichtung
Erscheinungsjahr
2024
Titel des Konferenzbandes
2024 Abstract Supplement ACR Convergence 2024 November 15–19, 2024 Washington, DC
Serien- oder Zeitschriftentitel
Arthritis & Rheumatology
Band
76
Ausgabe
Suppl. 9
Seite(n)
4772-4775
Konferenz
ACR Convergence 2024 November
Konferenzort
Washington, DC
Konferenzdatum
2024-11-15 – 2024-11-19
ISSN
2326-5191
eISSN
2326-5205
Page URI
https://pub.uni-bielefeld.de/record/2999816
Zitieren
Gensler LS, Marzo-Ortega H, Taieb V, et al. Achievement of Remission Defined by Absence of Objective Signs of Inflammation versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies. In: 2024 Abstract Supplement ACR Convergence 2024 November 15–19, 2024 Washington, DC. Arthritis & Rheumatology . Vol 76. Hoboken: Wiley; 2024: 4772-4775.
Gensler, L. S., Marzo-Ortega, H., Taieb, V., Voiniciuc, D., Marten, A., Stojan, G., Kim, M., et al. (2024). Achievement of Remission Defined by Absence of Objective Signs of Inflammation versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies. 2024 Abstract Supplement ACR Convergence 2024 November 15–19, 2024 Washington, DC, Arthritis & Rheumatology , 76, 4772-4775. Hoboken: Wiley. https://doi.org/10.1002/art.42992
Gensler, Lianne S., Marzo-Ortega, Helena, Taieb, Vanessa, Voiniciuc, Diana, Marten, Alexander, Stojan, George, Kim, Mindy, and Rudwaleit, Martin. 2024. “Achievement of Remission Defined by Absence of Objective Signs of Inflammation versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies”. In 2024 Abstract Supplement ACR Convergence 2024 November 15–19, 2024 Washington, DC, 76:4772-4775. Arthritis & Rheumatology . Hoboken: Wiley.
Gensler, L. S., Marzo-Ortega, H., Taieb, V., Voiniciuc, D., Marten, A., Stojan, G., Kim, M., and Rudwaleit, M. (2024). “Achievement of Remission Defined by Absence of Objective Signs of Inflammation versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies” in 2024 Abstract Supplement ACR Convergence 2024 November 15–19, 2024 Washington, DC Arthritis & Rheumatology , vol. 76, (Hoboken: Wiley), 4772-4775.
Gensler, L.S., et al., 2024. Achievement of Remission Defined by Absence of Objective Signs of Inflammation versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies. In 2024 Abstract Supplement ACR Convergence 2024 November 15–19, 2024 Washington, DC. Arthritis & Rheumatology . no.76 Hoboken: Wiley, pp. 4772-4775.
L.S. Gensler, et al., “Achievement of Remission Defined by Absence of Objective Signs of Inflammation versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies”, 2024 Abstract Supplement ACR Convergence 2024 November 15–19, 2024 Washington, DC, Arthritis & Rheumatology , vol. 76, Hoboken: Wiley, 2024, pp.4772-4775.
Gensler, L.S., Marzo-Ortega, H., Taieb, V., Voiniciuc, D., Marten, A., Stojan, G., Kim, M., Rudwaleit, M.: Achievement of Remission Defined by Absence of Objective Signs of Inflammation versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies. 2024 Abstract Supplement ACR Convergence 2024 November 15–19, 2024 Washington, DC. Arthritis & Rheumatology . 76, p. 4772-4775. Wiley, Hoboken (2024).
Gensler, Lianne S., Marzo-Ortega, Helena, Taieb, Vanessa, Voiniciuc, Diana, Marten, Alexander, Stojan, George, Kim, Mindy, and Rudwaleit, Martin. “Achievement of Remission Defined by Absence of Objective Signs of Inflammation versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies”. 2024 Abstract Supplement ACR Convergence 2024 November 15–19, 2024 Washington, DC. Hoboken: Wiley, 2024.Vol. 76. Arthritis & Rheumatology . 4772-4775.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in
Google Scholar